Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases

S J Aitken; J S Thomas; S P Langdon; D J Harrison; D Faratian

doi:10.1093/annonc/mdp427

Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases

S J Aitken, J S Thomas, S P Langdon, D J Harrison, D Faratian

Deanery of Molecular, Genetic and Population Health Sciences

Research output: Contribution to journal › Article › peer-review

Abstract

Assessment of receptors [estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2)] is routinely carried out on primary tumour in order to select appropriate adjuvant therapy; the same analysis is not carried out on nodal metastases. Since de novo resistance to therapy is common, we quantified differences in receptor expression between primary and nodal disease in order to assess whether this might contribute to therapeutic resistance.

Original language	English
Pages (from-to)	1254-61
Number of pages	8
Journal	Annals of Oncology
Volume	21
Issue number	6
DOIs	https://doi.org/10.1093/annonc/mdp427
Publication status	Published - 2010

Keywords

breast cancer
ER
HER2
image analysis
molecular phenotype
nodal metastases
PR

Access to Document

10.1093/annonc/mdp427

Cite this

@article{60827e77ba0e4123a852e3fa85ee4ce8,

title = "Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases",

abstract = "Assessment of receptors [estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2)] is routinely carried out on primary tumour in order to select appropriate adjuvant therapy; the same analysis is not carried out on nodal metastases. Since de novo resistance to therapy is common, we quantified differences in receptor expression between primary and nodal disease in order to assess whether this might contribute to therapeutic resistance.",

keywords = "breast cancer, ER, HER2, image analysis, molecular phenotype, nodal metastases, PR",

author = "Aitken, {S J} and Thomas, {J S} and Langdon, {S P} and Harrison, {D J} and D Faratian",

year = "2010",

doi = "10.1093/annonc/mdp427",

language = "English",

volume = "21",

pages = "1254--61",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "6",

}

TY - JOUR

T1 - Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases

AU - Aitken, S J

AU - Thomas, J S

AU - Langdon, S P

AU - Harrison, D J

AU - Faratian, D

PY - 2010

Y1 - 2010

N2 - Assessment of receptors [estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2)] is routinely carried out on primary tumour in order to select appropriate adjuvant therapy; the same analysis is not carried out on nodal metastases. Since de novo resistance to therapy is common, we quantified differences in receptor expression between primary and nodal disease in order to assess whether this might contribute to therapeutic resistance.

AB - Assessment of receptors [estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2)] is routinely carried out on primary tumour in order to select appropriate adjuvant therapy; the same analysis is not carried out on nodal metastases. Since de novo resistance to therapy is common, we quantified differences in receptor expression between primary and nodal disease in order to assess whether this might contribute to therapeutic resistance.

KW - breast cancer

KW - ER

KW - HER2

KW - image analysis

KW - molecular phenotype

KW - nodal metastases

KW - PR

UR - http://www.scopus.com/inward/record.url?scp=77951952801&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdp427

DO - 10.1093/annonc/mdp427

M3 - Article

C2 - 19858088

VL - 21

SP - 1254

EP - 1261

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 6

ER -

Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this